Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY) announced today the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. (NASDAQ: MGNX), including its biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of $122.5 million. The acquisition, conducted through Bora's wholly owned subsidiary Bora Biologics USA, LLC, also includes a long-term CDMO Service Agreement with MacroGenics.
With this transaction, Bora Biologics now operates 20,000 liters of single-use bioreactor (SUB) drug substance manufacturing capacity across two active US sites in Rockville, Maryland and San Diego, California, along with a development facility in Zhubei, Taiwan. The added capacity positions Bora to offer a fully integrated, end-to-end biologics platform spanning drug substance and drug product capabilities.
"This acquisition establishes a US biologics manufacturing platform that sponsors can depend on, from development through licensed commercial supply," said Bobby Sheng, Chairman and CEO of Bora Group. "As regulatory and supply chain dynamics continue to evolve, we expect biotech and pharmaceutical companies to increasingly seek manufacturing partners with US-based, inspection-proven infrastructure. Bora Biologics is designed to meet that need."
The Rockville facility adds to Bora's existing capabilities, which now support more than four active commercial programs and over 120 completed GMP batches supplied to global markets including the US, EU, Japan, Canada, and the UK. The combined platform has undergone five FDA inspections, including two at Rockville and one PMDA review in 2025, with clean results at both sites. It has supported more than 33 biologics and 15 biosimilars, providing a manufacturing base that reduces offshore dependency.
Bora Group intends to integrate its US drug substance capabilities with its existing sterile drug product capabilities over the next 12 to 18 months, offering a seamless development-through-commercial biologics solution. The company, founded in 2007, operates under a "Dual Engine" model combining CDMO and commercial expertise. For more information, visit https://www.bora-corp.com or https://www.boracdmo.com.
